Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 106,284,000
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.74
  • Price/Sales 6.68
  • Price/Cash Flow 17.95
  • Price/Book 18.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.05 +9.54%
on 04/27/17
41.97 -0.69%
on 05/23/17
+4.32 (+11.56%)
since 04/26/17
3-Month
32.89 +26.73%
on 03/08/17
41.97 -0.69%
on 05/23/17
+6.08 (+17.08%)
since 02/24/17
52-Week
30.89 +34.93%
on 11/23/16
57.44 -27.44%
on 06/07/16
-14.37 (-25.64%)
since 05/26/16

Most Recent Stories

More News
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio

Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs

OREX : 2.97 (+1.02%)
NVO : 41.68 (-0.43%)
VVUS : 1.13 (+0.89%)
ARNA : 1.31 (-3.68%)
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk

AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.

AZN : 33.85 (-1.43%)
NVO : 41.68 (-0.43%)
MRK : 64.92 (-0.18%)
LLY : 78.05 (-0.37%)
Sams and Dahl Strengthen Leadership Team With Appointment to Team Novo Nordisk Board of Directors

Joining immediately are Turner Broadcasting System Executive Vice President and General Counsel, Louise Sams, and Jens Carsten Dahl, Novo Nordisk Vice President and Executive Assistant to the President...

NVO : 41.68 (-0.43%)
SmarTrend Watching for Potential Pullback in Shares of Novo Nordisk After 1.18% Gain

Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $40.84 to a high of $41.04. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $40.94...

NVO : 41.68 (-0.43%)
PHA Announces New Partners at 2017 Summit Day One

Today, the Partnership for a Healthier America's (PHA) sixth-annual Building a Healthier Future Summit kicked off with remarks from President Bill Clinton and Tricia Brooks, Vice President, Public Affairs...

NVO : 41.68 (-0.43%)
PEP : 117.91 (+0.32%)
Next Generation Diabetes Therapy and Drug Delivery Market - Key Players are Abbott Labs, Medtronic, Sanofi, Novo Nordisk, MannKind, Dexcom, Senseonics Holding, Medtech and Johnson & Johnson - Research and Markets

Research and Markets has announced the addition of the "Next Generation Diabetes Therapy and Drug Delivery Market by Product Type, Demographic, Indication and End Users - Global Opportunity...

NVO : 41.68 (-0.43%)
MDT : 85.09 (-0.57%)
Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y

Novo Nordisk A/S (NVO) reported first-quarter 2017 earnings of 58 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 53 cents by 9.4%.

AGLE : 4.50 (+1.58%)
GALE : 0.56 (-3.45%)
NVO : 41.68 (-0.43%)
INFI : 1.72 (-1.15%)
NNIT A/S: 4/2017 Novo Nordisk renews corporate core IT infrastructure agreement with NNIT

Company announcement 4/2017

NVO : 41.68 (-0.43%)
Watch for Novo Nordisk to Potentially Pullback After Gaining 5.24% Yesterday

Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $40.96 to a high of $41.57. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high of $39.19...

NVO : 41.68 (-0.43%)
Novo Nordisk Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in the United States

Novo Nordisk, a world leader in diabetes care, today announced the availability of its new combination therapy Xultophy® 100/3.6 (insulin degludec and liraglutide injection, 100 units/mL and 3.6 mg/mL)...

NVO : 41.68 (-0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 42.03
1st Resistance Point 41.85
Last Price 41.68
1st Support Level 41.50
2nd Support Level 41.33

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.